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ABSTRACT
Aim of the study. Oral anticoagulants, preferentially vitamin K antagonists (VKA), are recommended for 3–12 months in 
patients with cerebral venous sinus thrombosis (CVST). We present a series of patients with CVST treated with direct oral anti-
coagulants (DOAC).
Materials and methods. We prospectively recruited 36 patients with CVST (aged 40.3 ± 9.2 years, 58.3% female) treated with DOAC 
based on the physician’s or patient’s preferences. Functional outcome was assessed with modified Rankin Scale. Recanalisation was 
assessed on imaging at 3–6 months post the event. Patients were followed for a median of 30 [interquartile range (IQR) 25–37] months.
Results. After use of heparin (median: 6 days; IQR 5–8.75), patients received dabigatran (150 mg bid, n = 16 or 110 mg bid, n = 
2), rivaroxaban (20 mg qd, n = 10) or apixaban (5 mg bid, n = 8) for a median of 8.5 months (IQR 6.25–12). Complete or partial 
recanalisation was observed in 34 cases (94.4%). Three patients (8.3%) experienced major bleeding: menorrhagia on rivaroxa-
ban (n = 2) and gastrointestinal bleeding on dabigatran (n = 1). A favourable functional outcome was observed in 24 (66.7%) 
patients, without any fatality. CSVT recurred in two patients (5.6%) and two venous thromboses developed in two other patients 
with inherited thrombophilia after anticoagulation withdrawal.
Conclusions and clinical implications. DOACs could be an alternative to VKA in CVST patients.
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Introduction
Cerebral venous sinus thrombosis (CVST) is rare, with 
an annual incidence estimated at 3 to 4 cases per million [1] 
and with a female to male ratio of 3:1 [2]. CVST is associated 
with genetic or acquired thrombophilias, malignancy, infec-
tion or head trauma, pregnancy, and oral contraceptives [3]. 
Prothrombotic risk factors are identifiable among 85% of 
CVST patients [3].
European Stroke Organisation guidelines recommend 
using low-molecular-weight heparin (LMWH) in the treat-
ment of the acute phase [4], followed by vitamin K antagonists 
(VKAs) for 3–12 months. The guidelines of the American 
Heart Association/American Stroke Association are similar [5].
Direct oral anticoagulants (DOACs) are at least as effective 
as VKAs in the treatment and prevention of the recurrence 
of venous thromboembolism (VTE) [6]. DOACs might be 
a promising alternative to VKAs in the long-term treatment of 
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CVST, especially among patients for whom VKAs are contra-
indicated or unsuitable [7].There have been few observational 
studies on DOAC in CVST. Mendonça et al. [8] reported full 
recanalisation in 27% of 15 dabigatran-treated CVST patients 
(mostly 150 mg bid) and excellent long-term functional 
outcomes in 87% of patients, without any CVST recurrence or 
major bleeding during follow-ups for a median of 19 months. 
Geisbüsch et al. [9] reported on seven patients with CVST on 
rivaroxaban 20 mg qd. During follow-up (median: 7 months), 
no thrombotic events and two minor bleeds occurred. Com-
plete recanalisation was observed in four patients.
Several experts have advised using DOAC in this disease 
[6]. To the best of our knowledge, there have been no reports 
on Polish patients with CVST treated with DOACs. This single-
-centre case series study was aimed to assess the efficacy and 
safety of DOACs in CVST.
Materials and methods
We enrolled 36 consecutive patients with a documented 
episode of CVST referred for further diagnostic work-up to an 
outpatient clinic at John Paul II Hospital in Krakow, Poland, 
between December 2013 and March 2018. On the first visit, all 
eligible subjects were on dabigatran, rivaroxaban or apixaban 
and provided medical records including imaging data. They 
were enrolled 3–6 months since a diagnosis of CVST. The 
exclusion criteria were as follows: indications for long-term 
anticoagulant therapy other than VTE, diagnosed malignancy, 
pregnancy, breastfeeding, and advanced kidney disease (sta-
ge 4–5). Written consent was obtained to participate in this 
observational study.
Clinical diagnosis of CVST was made according to the 
international criteria [5] by brain imaging — computed to-
mography (CT) with CT venography. Following the use of 
LMWH at therapeutic doses or unfractionated heparin, the 
DOAC therapy was initiated. To assess the vessel recanalisation 
status, CT angiography was performed 3–6 months after CVST.
We collected demographic characteristics, clinical data on 
CVST, VTE risk factors, comorbidities and current treatment 
using a standardised questionnaire. Unprovoked CVST was 
established if there was no history of malignancy, major sur-
gery, trauma, immobilisation, pregnancy or childbirth at least 
three months before CVST diagnosis and no use of oestrogen. 
Family history of VTE was defined as VTE in first-degree 
relatives. Obesity was recognised when Body Mass Index was 
≥ 30 kg/m2. 
Follow-up included the time of DOAC use and the time 
since its withdrawal. Clinical data was collected every six 
months via a visit to the outpatient clinic or telephone contact. 
The decision to cease DOAC use was left to the discretion of 
the attending physician based on the patient’s preferences. 
Thrombophilia screening was performed (antiphospholipid 
syndrome [APS], Factor V Leiden [FVL] or prothrombin 
G20210A mutations and deficiencies in protein C, protein 
S or antithrombin, as described previously [10]). Functional 
outcome was assessed using modified Rankin Scale (mRS) 
before initiation of the DOAC therapy and after 6–12 months 
of follow-up. A favourable functional outcome was defined as 
0-1 point in mRS. The occurrence of VTE (including CVST) 
and major bleeding (according to the definition by Schulman 
et al. [11]) were recorded.
The local ethical committee issued approval for the study 
according to the Declaration of Helsinki.
Statistical analysis
Categorical variables were reported as numbers and 
percentages. Continuous variables were presented as means 
(standard deviation) or median (IQR, interquartile range). 
Normality was assessed by the Shapiro-Wilk test. The chi-
-squared test was used to compare categorical variables. The 
ANOVA or Kruskal-Wallis tests for continuous variables 
were conducted to assess differences between the groups 
using different DOACs. Analyses were performed using SPSS 
Software (IBM, USA). A P-value below 0.05 was considered 
statistically significant.
Results
A total of 36 patients with CVST (aged 40.3 ± 9.2 years, 
58.3% female) were analysed (Table 1). Unprovoked CVST was 
found in 26 (72.2%). Thrombophilia was observed in 18 (50%) 
patients, including eight patients (22.2%) with FVL.
The most common single location of CVST was the 
transverse sinus. Following the use of heparin (median, 
6 days; IQR 5–8.75), DOAC was initiated and continued 
for a median of 8.5 months (IQR 6.25–12). There were 
18 patients (50%) on dabigatran (n = 16, 150 mg bid and n 
= 2, 110 mg bid). Ten subjects (27.8%) received rivaroxaban 
(20 mg daily) and eight patients (22.2%) were on apixaban 
(5 mg bid). Apart from older age in the dabigatran users 
(44.3 ± 8.3 years vs. rivaroxaban 35.7 ± 9.1 and apixaban 
37.1 ± 8.4 years, p = 0.029), the patients on the three DO-
ACs were similar with regard to demographic and clinical 
characteristics (data not shown).
A repeat brain imaging after 3–6 months showed at least 
partial vessel recanalisation in 34 patients (94.4%). Complete 
recanalisation was observed in 20 individuals (55.6%), com-
prising 10 on dabigatran (55.6%), six on rivaroxaban (60.0%) 
and four on apixaban (50.0%).
 On anticoagulant therapy, three patients (8.3%), two on 
rivaroxaban (20 mg qd) and one on dabigatran (110 mg bid), 
experienced major bleeding, including two heavy menstrual 
bleedings (HMB) in a 25-year-old woman and a 46-year-old 
woman both with previously abundant menses (haemoglobin, 
8 g/dL and 9 g/dL, respectively) and an upper gastrointestinal 
bleeding in a 56-year-old woman who had reported dysphagia 
in previous weeks despite pantoprazole use.
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Table 1. Characteristics of the study participants
VARIABLE TOTAL (n = 36)
Age, years 40.3 ± 9.2
Sex female, n (%) 21 (58.3%)
BMI [kg/m2] 26.8 ± 4.2
Cigarette smoking, n (%) 8 (22.2%)
OC/HRT, n/females (%) 10/21 (47.6%)
Family history of VTE, n (%) 8 (22.2%)
Unprovoked CVST, n (%) 26 (72.2%)
Obesity, n (%) 10 (27.8%)
Site of CVST
Transverse sinus, n (%) 5 (13.9%)
Cavernous sinus, n (%) 3 (8.3%)
Straight sinus, n (%) 1 (2.8%)
Combined, n (%) 26 (72.2%)
Other locations, n (%) 1 (2.8%)
Concomitant VTE, n (%) 4 (11.1%)
Heparin regimen
LMWH, n (%) 33 (91.7%)
UFH, n (%) 3 (8.3%)
Duration of heparin use [days] 6 (5–8.75)
Aspirin use, n (%) 8 (22.2%)
Type of DOAC
Dabigatran, n (%) 18 (50.0%)
Rivaroxaban, n (%) 10 (27.8%)
Apixaban, n (%) 8 (22.2%)
Full dose of DOAC, n (%) 34 (94.4%)
Duration of DOAC use [months] 8.5 (6.25–12)
mRS score at the start of DOAC
Favourable outcome (mRS 0–1), n (%) 19 (52.8%)
Independent (mRS 2), n (%) 13 (36.1%)
Significant disability (mRS 3–5), n (%) 4 (11.1%)
Follow-up [months] 30 (25–37)
Recanalisation 3-6 months after CVST
Complete, n (%) 20 (55.6%)
Partial, n (%) 14 (38.9%)
No recanalisation, n (%) 2 (5.6%)
mRS score 6-12 months after CVST
Favourable outcome (mRS 0–1), n (%) 24 (66.7%)
Independent (mRS 2), n (%) 10 (27.8%)
Significant disability (mRS 3–5) , n (%) 2 (5.6%)
Recurrent CSVT, n (%) 2 (5.6%)
New DVT, n (%) 2 (5.6%)
Major bleeding, n (%) 3 (8.3%)
Thrombophilia testing 
Factor V Leiden, n (%) 8 (22.2%)
Prothrombin G20210A mutation, n (%) 3 (8.3%)
Protein C deficiency, n (%) 1 (2.8%)
Protein S deficiency, n (%) 2 (5.6%)
Antithrombin deficiency, n (%) 1 (2.8%)
Antiphospholipid syndrome, n (%) 4 (11.1%)
Data reported as median (interquartile range), mean ± standard deviation or number (percentage)
BMI — Body Mass Index; CVST — cerebral venous sinus thrombosis; DVT — deep vein thrombosis; 
LMWH — low-molecular-weight heparin; mRS — modified Rankin Scale; DOAC — direct oral anti-
coagulant; OC/HRT — oral contraceptives/hormonal replacement therapy; UFH — unfractionated 
heparin; VTE — venous thromboembolism
After withdrawal of anticoagulant therapy, we followed 
patients for a median of 30 months (IQR 25–37). Neuro-
logical evaluation at 6–12 months showed that 66.7% of 
CVST patients (n = 24) had a favourable functional outco-
me. During follow-up, two patients (5.6%) had recurrent 
CVST. One episode occurred in a 37-year-old man, free 
of thrombophilia but with a positive VTE family history, 
five months after rivaroxaban withdrawal. The other was 
diagnosed in a 52-year-old woman, diagnosed with single-
-positive APS, following hospitalisation for pneumonia, 
20 months after the first CSVT, while on aspirin. There 
were also two episodes of deep-vein thrombosis (DVT). 
The first DVT event, provoked by a leg injury and oral con-
traception, occurred in a 29-year-old woman heterozygous 
for prothrombin G20210A mutation with previous VTE, 
18 months after apixaban therapy was ended. The other 
unprovoked DVT was observed in a 46-year-old woman 
heterozygous for FVL.
Discussion
To the best of our knowledge, this is the first Polish case 
study and the largest worldwide report presenting treatment 
outcomes among DOAC-treated patients with CVST.
We noted complete cerebral vessel recanalisation in more 
than 55% of rivaroxaban users, which is similar to the previous 
study [9], in which such an outcome was observed in 57.1% 
of cases. Among dabigatran-treated patients, the complete 
recanalisation rate was 60% (n = 6), which is much higher 
than in a Portuguese study [8] where full recanalisation was 
noted in 26.7% of patients. The favourable functional outcomes 
during follow-up were similar to previous studies [8–9] while 
a favourable functional outcome was observed in 58–89% of 
CVST patients on warfarin [12–13].
Since among VKA-treated patients with CVST, the major 
bleeding rate is estimated at 0.21%/patient-month [14], the 
present rate with 8.3% of patients (n = 3) with major bleeding 
over a median of 8.5 months of DOAC therapy appears to 
be higher. However, there were no life-threatening episodes 
and the 50% lower risk of intracranial bleeds on DOAC is of 
vital importance. We confirmed an increased HMB risk 
on this drug [15–16], which supports the suggestion 
that in women of reproductive age and previously 
abundant menses, rivaroxaban should be avoided. 
Previous small studies [8–9] did not report any major hae-
morrhages, which disagrees with randomised VTE studies 
and registries [17–18].
Two recurrent episodes of CVST while off anticoagulation 
are consistent with the rates reported in previous studies, i.e. 
2–4.4% over a median 16–40 months of follow-up (0.5–1.5 per 
100 person-years) [3, 12]. Regarding non-cerebral VTE, the 
current two episodes among 36 CVST patients correspond to 
the rate for VKA-treated CVST patients (6.5% over a median 
follow-up of 40 months) [12].
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Clinical implications/future directions
While we await the results of a randomised trial with dabi-
gatran in CVST patients [19], based on growing evidence from 
observational studies, DOACs do appear to be an attractive 
alternative to VKA due to similar efficacy and safety without 
even taking into account advantages including no need for 
laboratory monitoring, no dietary interactions, and no inter-
ference with most medications [20]. Randomised trials with 
all DOACs should be performed to prove the benefits available 
from DOACs in this disease.
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